Emami (HMN) posted a beat on all fronts in its 2QFY21 results. Importantly, (a) strengthening rural growth (50% of HMN's sales), (b) extremely strong health and hygiene sales, (c) initial good winter demand, and (d) the low winter season sales base of last year augur well for sales and earnings growth over the next few quarters. We remain bullish on the stock, despite two primary concerns. (a) The likely delay in pledge reduction to zero (earlier targeted by Mar'21; currently at ~40% levels) is disappointing. (b) There is no evidence of a structural...